Theravance Biopharma Stock Performance
| TBPH Stock | USD 9.12 0.02 0.22% |
The entity has a beta of 0.21, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Theravance Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Theravance Biopharma is expected to be smaller as well. Theravance Biopharma has an expected return of -0.0796%. Please make sure to validate Theravance Biopharma skewness, and the relationship between the treynor ratio and rate of daily change , to decide if Theravance Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Theravance Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Theravance Biopharma is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return (0.22) | Five Day Return (2.15) | Year To Date Return (21.31) | Ten Year Return (60.28) | All Time Return (60.28) |
1 | Disposition of 18219 shares by Rhonda Farnum of Theravance Biopharma at 8.92 subject to Rule 16b-3 | 02/20/2024 |
2 | Theravance Biopharma earnings missed by 0.02, revenue topped estimates | 02/26/2024 |
3 | Theravance Biopharma Full Year 2023 Earnings EPS Misses Expectations | 02/28/2024 |
4 | Theravance Biopharma, Inc. Shares Sold by Barclays PLC - AmericanBankingNEWS | 03/01/2024 |
5 | Equities Analysts Offer Predictions for Theravance Biopharma, Inc.s Q1 2024 Earnings - Defense World | 03/08/2024 |
6 | Theravance Biopharma, Inc. to Post Q1 2024 Earnings of Per Share, Zacks Research Forecasts - MarketBeat | 03/18/2024 |
7 | Acquisition by Rick Winningham of 00 shares of Theravance Biopharma subject to Rule 16b-3 | 03/19/2024 |
8 | Why Is Theravance Bio Down 9 percent Since Last Earnings Report | 03/27/2024 |
9 | Acquisition by Rhonda Farnum of 37500 shares of Theravance Biopharma subject to Rule 16b-3 | 04/02/2024 |
10 | Theravance Biopharma Options Chain Prices 2024 - MarketBeat | 04/04/2024 |
11 | BTIG starts Theravance Biopharma stock on BUY, cites pivotal data for ampreloxetine | 04/12/2024 |
12 | Theravance Biopharma Reports Q1 Loss, Lags Revenue Estimates - Yahoo Movies UK | 04/16/2024 |
13 | Disposition of 37500 shares by Aine Miller of Theravance Biopharma at 25.42 subject to Rule 16b-3 | 04/26/2024 |
| Begin Period Cash Flow | 299 M |
Theravance |
Theravance Biopharma Relative Risk vs. Return Landscape
If you would invest 977.00 in Theravance Biopharma on January 30, 2024 and sell it today you would lose (65.00) from holding Theravance Biopharma or give up 6.65% of portfolio value over 90 days. Theravance Biopharma is currently does not generate positive expected returns and assumes 2.4575% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Theravance, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Theravance Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Theravance Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Theravance Biopharma, and traders can use it to determine the average amount a Theravance Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0324
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TBPH |
Estimated Market Risk
| 2.46 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Theravance Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Theravance Biopharma by adding Theravance Biopharma to a well-diversified portfolio.
Theravance Biopharma Fundamentals Growth
Theravance Stock prices reflect investors' perceptions of the future prospects and financial health of Theravance Biopharma, and Theravance Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Theravance Stock performance.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.0673 | ||||
| Profit Margin | (0.96) % | ||||
| Operating Margin | (0.36) % | ||||
| Current Valuation | 386 M | ||||
| Shares Outstanding | 48.56 M | ||||
| Price To Earning | (6.20) X | ||||
| Price To Book | 2.19 X | ||||
| Price To Sales | 8.13 X | ||||
| Revenue | 57.42 M | ||||
| Gross Profit | (12.05 M) | ||||
| EBITDA | (40.28 M) | ||||
| Net Income | (55.19 M) | ||||
| Cash And Equivalents | 132.85 M | ||||
| Cash Per Share | 1.74 X | ||||
| Total Debt | 45.24 M | ||||
| Debt To Equity | 652.20 % | ||||
| Current Ratio | 4.74 X | ||||
| Book Value Per Share | 4.43 X | ||||
| Cash Flow From Operations | (27 M) | ||||
| Earnings Per Share | (1.00) X | ||||
| Market Capitalization | 442.87 M | ||||
| Total Asset | 382 M | ||||
| Retained Earnings | (909.1 M) | ||||
| Working Capital | 108.77 M | ||||
| Current Asset | 237.47 M | ||||
| Current Liabilities | 49.47 M | ||||
About Theravance Biopharma Performance
To evaluate Theravance Biopharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Theravance Biopharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Theravance Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Theravance Biopharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Theravance's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00006 | 0.000057 | |
| Return On Tangible Assets | (0.14) | (0.15) | |
| Return On Capital Employed | (0.15) | (0.14) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | (0.26) | (0.25) |
Things to note about Theravance Biopharma performance evaluation
Checking the ongoing alerts about Theravance Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Theravance Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Theravance Biopharma generated a negative expected return over the last 90 days | |
| Theravance Biopharma has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 57.42 M. Net Loss for the year was (55.19 M) with loss before overhead, payroll, taxes, and interest of (12.05 M). | |
| Theravance Biopharma currently holds about 132.85 M in cash with (27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.74. | |
| Theravance Biopharma has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Theravance Biopharma Reports Q1 Loss, Lags Revenue Estimates - Yahoo Movies UK |
- Analyzing Theravance Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Theravance Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Theravance Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Theravance Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Theravance Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Theravance Biopharma's stock. These opinions can provide insight into Theravance Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theravance Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.00) | Revenue Per Share 1.038 | Quarterly Revenue Growth 0.199 | Return On Assets (0.07) | Return On Equity (0.17) |
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.